BB BIOTECH N

BB Biotech and Medpace are among the stocks traders are currently backing, as AI-supported models could accelerate drug development and spark broader innovation across the sector. After years dominated by GLP-1 and individual blockbusters, multiple biotech companies could now benefit from more efficient drug discovery and new discoveries. The article names three biotech stocks at 52-week highs that traders should keep an eye on. » Más en finanzen.net

Last trading week, numerous analysts advised exiting various stocks and issued multiple sell recommendations. At the same time, BB Biotech reported a stronger comeback with solid quarterly results and a portfolio that outperforms the industry index, while the stock still lags its intrinsic value. » Más en finanzen.net

BB Biotech recorded a NAV increase of 17.2% in CHF/eur (15.9% in USD) in Q2 and a quarterly profit of CHF 451m versus a loss in the prior year. The portfolio outperformed the Nasdaq Biotechnology Index by 3.5 percentage points, while the stock returned 9.7% and lagged the intrinsic value, with the discount widening to 12.9%. Management accelerated the realignment (12 new additions in the quarter) and increased weightings in large biotech names such as Amgen, Argenx, Vertex and Gilead; about 7% of NAV is held in liquid assets. Additional tailwinds come from recent sector takeovers and a new distribution policy (target yield 3–5%, first payment spring 2027); risks remain from price regulation, interest rates and clinical failures. » Más en finanzen.net